Apolipoprotein A5 T-1131C variant and risk for metabolic syndrome in obese adolescents

Gene

Volumn 534, Issue 1, 2014, Pages 44-47

  Zaki, Moushira ^a   Amr, Khalda ^a  

^a NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

ApoA5 T 1131C; Metabolic syndrome; Obesity

Indexed keywords

APOLIPOPROTEIN A5; CHOLESTEROL; CYSTEINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; THREONINE; TRIACYLGLYCEROL;

ADOLESCENT; ADOLESCENT DISEASE; ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC PARAMETERS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HARDY WEINBERG DISTRIBUTION LAW; HETEROZYGOTE; HOMEOSTASIS MODEL ASSESSMENT FOR INSULIN RESISTANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT;

APOA5 T-1131C; APOB; APOLIPOPROTEIN B; BLOOD PRESSURE; BMI; BODY MASS INDEX; BP; CI; CONFIDENCE INTERVAL; DEOXYRIBONUCLEIC ACID; DEOXYRIBONUCLEOSIDE TRIPHOSPHATE; DNA; DNTP; HDL-C; HIGH-DENSITY LIPOPROTEIN CHOLESTEROL; HOMA-R; HOMEOSTASIS MODEL ASSESSMENT FOR INSULIN RESISTANCE; IDF; INTERNATIONAL DIABETES FEDERATION; LDL-C; LOW-DENSITY LIPOPROTEIN CHOLESTEROL; METABOLIC SYNDROME; MS; NUCLEOTIDE POLYMORPHISMS; OBESITY; ODDS RATIO; OR; PCR; POLYMERASE CHAIN REACTION; SDLDL; SMALL DENSE LOW-DENSITY LIPOPROTEIN; SNPS; SPSS; STATISTICAL PACKAGE FOR THE SOCIAL SCIENCES; TGS; TRIGLYCERIDES; VERY LOW DENSITY LIPOPROTEIN; VLDL; WAIST CIRCUMFERENCE; WC;

ADOLESCENT; APOLIPOPROTEINS A; CASE-CONTROL STUDIES; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HUMANS; MALE; METABOLIC SYNDROME X; OBESITY; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; YOUNG ADULT;

EID: 84888021172     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.10.032     Document Type: Article

References (43)

1. Charriere S., et al. Association of APOA5 -1131T>C and S19W gene polymorphisms with both mild hypertriglyceridemia and hyperchylomicronemia in type 2 diabetic patients. Clin. Chim. Acta 2008, 1-2:99-103.
2. Dorfmeister B., Cooper J.A., Stephens J.W., Ireland H., Hurel S.J., Humphries S.E., Talmud P.J. The effect of APOA5 and APOC3 variants on lipid parameters in European Whites, Indian Asians and Afro-Caribbeans with type 2 diabetes. Biochim. Biophys. Acta 2007, 1772:355-363.
3. Eckel R.H., Grundy S.M., Zimmet P.Z. The metabolic syndrome. Lancet 2005, 365:1415-1428.
4. Girona J., et al. The APOA5-1131T>C polymorphism affects vitamin E plasma concentrations in type 2 diabetic patients. Clin. Chem. Lab. Med. 2008, 46:453-457.
5. Grallert H., Sedlmeier E.M., Huth C., Kolz M., Heid I.M., Meisinger C., et al. APOA5 variants and metabolic syndrome in Caucasians. J. Lipid Res. 2007, 48:2614-2621.
6. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
7. Havasi V., Szolnoki Z., Talián G., Bene J., Komlósi K., Maász A., et al. Apolipoprotein A5 gene promoter region T-1131C polymorphism associates with elevated circulating triglyceride levels and confers susceptibility for development of ischemic stroke. J. Mol. Neurosci. 2006, 29:177-183.
8. Henneman P., et al. Plasma apoAV levels are markedly elevated in severe hypertriglyceridemia and positively correlated with the APOA5 S19W polymorphism. Atherosclerosis 2006, 193:129-134.
9. Horvatovich K., et al. Haplotype analysis of the apolipoprotein A5 gene in obese pediatric patients. Int. J. Pediatr. Obes. 2011 Jun, 6(2):e318-e325.
10. Hubacek J.A., Skodová Z., Lánská V., Adámková V. Apolipoprotein A-V variant (T-1131>C) affects plasma levels of non-high-density lipoprotein cholesterol in Caucasians. Exp. Clin. Cardiol. 2008, 3:129-132.
11. Hubácek J.A., Adámková V., Vrablík M, Kadlecová M., Zicha J., Kunes J., et al. Apolipoprotein A5 in health and disease. Physiol. Res. 2009, 58:S101-S109.
12. International Diabetes Federation Worldwide definition of the metabolic syndrome Available at, (Accessed 19/05/2012). http://www.idf.org/webdata/docs/MetSyndrome_FINAL.pdf.
13. Jakel H., Nowak M., Moitrot E., Dehondt H., Hum D.W., Pennacchio L.A, et al. The liver X receptor ligand T0901317 down-regulates APOA5 gene expression through activation of SREBP-1c. J. Biol. Chem. 2004, 279:45462-45469.
14. Jang Y., Kim J.Y., Kim O.Y., Lee J.E., Cho H., Ordovas J.M., et al. The -1131T>C polymorphism in the apolipoprotein A5 gene is associated with postprandial hypertriacylglycerolemia; elevated small, dense LDL concentrations; and oxidative stress in nonobese Korean men. Am. J. Clin. Nutr. 2004, 80:832-840.
15. Járomi L., et al. Functional variants of glucokinase regulatory protein and apolipoprotein A5 genes in ischemic stroke. J. Mol. Neurosci. 2010, 41(1):121-128.
16. Járomi L., et al. Functional variants of glucokinase regulatory protein and apolipoprotein A5 genes in ischemic stroke. J. Mol. Neurosci. 2010, 41(1):121-128.
17. Kao J.T., Wen H.C., Chien K.L., Hsu H.C., Lin S.W. A novel genetic variant in the apolipoprotein A5 gene is associated with hypertriglyceridemia. Hum. Mol. Genet. 2003, 12:2533-2539.
18. Kathiresan S., et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat. Genet. 2008, 2:189-197.
19. Kisfali P., et al. Apolipoprotein A5 IVS3+476A allelic variant associates with increased triglyceride levels and confers risk for development of metabolic syndrome in Hungarians. Circ. J. 2008, 72:40-43.
20. Kisfali P., et al. Triglyceride level affecting shared susceptibility genes in metabolic syndrome and coronary artery disease. Curr. Med. Chem. 2010, 17(30):3533-3541.
21. Kisfali P., et al. Haplotype analysis of the apolipoprotein A5 gene in patients with the metabolic syndrome. Nutr. Metab. Cardiovasc. Dis. 2010, 20(7):505-511.
22. Lai C.Q., Tai E.S., Tan C.E., Cutter J., Chew S.K., Zhu Y.P., et al. The APOA5 locus is a strong determinant of plasma triglyceride concentrations across ethnic groups in Singapore. J. Lipid Res. 2003, 44:2365-2373.
23. Lai C.Q., Demissie S., Cupples L.A., Zhu Y., Adiconis X., Parnell L.D., et al. Influence of the APOA5 locus on plasma triglyceride, lipoprotein subclasses, and CVD risk in the Framingham Heart Study. J. Lipid Res. 2004, 45:2096-2105.
24. Lee K.W., Ayyobi A.F., Frohlich J.J., Hill J.S. APOA5 gene polymorphism modulates levels of triglyceride, HDL cholesterol and FERHDL but is not a risk factor for coronary artery disease. Atherosclerosis 2004, 176:165-172.
25. Maasz A., Kisfali P., Horvatovich K., Mohás M., Markó L., Csöngei V., et al. Apolipoprotein A5 T-1131C variant confers risk for metabolic syndrome. Pathol. Oncol. Res. 2007, 13:243-247.
26. Maasz A., et al. Apolipoprotein A5 gene IVS3+G476A allelic variant confers susceptibility for development of ischemic stroke. Circ. J. 2008, 7:1065-1070.
27. Mar R., Pajukanta P., Allayee H., Groenendijk M., Dallinga-Thie G., Krauss R.M., et al. Association of the APOLIPOPROTEIN A1/C3/A4/A5 gene cluster with triglyceride levels and LDL particle size in familial combined hyperlipidemia. Circ. Res. 2004, 94:993-999.
28. Mar R., Pajukanta P., Allayee H., Groenendijk M., Dallinga-Thie G., Krauss R.M., et al. Association of the apolipoprotein A1/C3/A4/A5 gene cluster with triglyceride levels and LDL particle size in familial combined hyperlipidemia. Circ. Res. 2004, 94:993-999.
29. Marcais C., et al. Apoa5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment. J. Clin. Invest. 2005, 115:2862-2869.
30. Martinelli N., Trabetti E., Bassi A., Girelli D., Friso S., Pizzolo F., et al. The -1131T>C and S19W APOA5 gene polymorphisms are associated with high levels of triglycerides and apolipoprotein C-III, but not with coronary artery disease: an angiographic study. Atherosclerosis 2007, 191:409-417.
31. Mathews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Teacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985, 28:412-419.
32. Nabika T., Nasreen S., Kobayashi S., Masuda J. The genetic effect of the apoprotein AV gene on the serum triglyceride level in Japanese. Atherosclerosis 2002, 165:201-204.
33. Niculescu L.S., Fruchart-Najib J., Fruchart J.C., et al. Apolipoprotein A-V gene polymorphisms in subjects with metabolic syndrome. Clin. Chem. Lab. Med. 2007, 45:1133-1139.
34. Ortega H., Castilla P., Mez-Coronado D., Garcés C., Benavente M., Rodríguez-Artalejo F., et al. Influence of apolipoprotein E genotype on fat-soluble plasma antioxidants in Spanish children. Am. J. Clin. Nutr. 2005, 81:624-632.
35. Pennacchio L.A., Olivier M., Hubacek J.A., Cohen J.C., Cox D.R., Fruchart J.C., et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 2001, 294:169-173.
36. Pennacchio L.A., Olivier M., Hubacek J.A., Krauss R.M., Rubin E.M., Cohen J.C. Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. Hum. Mol. Genet. 2002, 11:3031-3038.
37. Priore Oliva C., et al. A novel sequence variant in APOA5 gene found in patients with severe hypertriglyceridemia. Atherosclerosis 2006, 188:215-217.
38. Qi L., Liu S., Rifai N., Hunter D., Hu F.B. Associations of the apolipoprotein A1/C3/A4/A5 gene cluster with triglyceride and HDL cholesterol levels in women with type 2 diabetes. Atherosclerosis 2007, 192:204-210.
39. Talmud P.J., Hawe E., Martin S., Olivier M., Miller G.J., Rubin E.M., et al. Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. Hum. Mol. Genet. 2002, 11:3039-3046.
40. Talmud P.J., et al. APOA5 gene variants, lipoprotein particle distribution, and progression of coronary heart disease: results from the LOCAT study. J. Lipid Res. 2004, 45:750-756.
41. Tang Y., Sun P., Guo D., Ferro A., Ji Y., Chen Q., et al. A genetic variant c.553G>T in the apolipoprotein A5 gene is associated with an increased risk of coronary artery disease and altered triglyceride levels in a Chinese population. Atherosclerosis 2006, 185:433-437.
42. van der Vliet H.N., Sammels M.G., Leegwater A.C., Levels J.H., Reitsma P.H., Boers W., et al. Apolipoprotein A-V: a novel apolipoprotein associated with an early phase of liver regeneration. J. Biol. Chem. 2001, 276:44512-44520.
43. Willer C.J., et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat. Genet. 2008, 2:161-169.